BioSpectrum India Magazine
By: Bio Spectrum And NuFFooDs Spectrum- BioSpectrum India September 2021
- Price : 100.00
- Published on August 30, 2021
- Bio Spectrum And NuFFooDs Spectrum
- Issues 58
- Language - English
- Published monthly
About this issue
GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry . For Feedback, please email us at : communications@mmactiv.com --
About BioSpectrum India Magazine
The BioSpectrum India edition was launched in March 2003 and is India's first comprehensive biotech business monthly magazine. It provides comprehensive coverage of the exciting happenings in life sciences, which include BioPharma, BioAgriculture, BioInformatics, BioIndustrial, BioSuppliers and BioServices and show cases the emerging Indian entrepreneurships in biotech industry. In a short time BioSpectrum has emerged as the most preferred platform to engage the life sciences industry in India and Asia Pacific. It is also widely accepted by research and academia community. Top key policy makers in the Central and state government use the magazine as a platform to reach out the Indian Biotech Industry. BioSpectrum has columns by Indian's top policy makers, biotechnology professionals, scientists and NGOs. Readers of BioSpectrum are from among the key Policy Makers, Key Executives and the Influencer's in Biotechnology, Pharmaceutical Companies, Research Heads of Clinical Research, Clinical Trials and Contract Mfg Organizations, Educational Institutes, Consultants, Fund Managers etc